These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 35285867)
21. Exertional Heat Stroke and Susceptibility to Malignant Hyperthermia in an Athlete: Evidence for a Link? Poussel M; Guerci P; Kaminsky P; Heymonet M; Roux-Buisson N; Faure J; Fronzaroli E; Chenuel B J Athl Train; 2015 Nov; 50(11):1212-4. PubMed ID: 26565425 [TBL] [Abstract][Full Text] [Related]
22. Malignant Hyperthermia Susceptibility and Fitness for Duty. Lee MA; McGlinch EB; McGlinch MC; Capacchione JF Mil Med; 2017 Mar; 182(3):e1854-e1857. PubMed ID: 28290972 [TBL] [Abstract][Full Text] [Related]
23. Strenuous exercise triggers a life-threatening response in mice susceptible to malignant hyperthermia. Michelucci A; Paolini C; Boncompagni S; Canato M; Reggiani C; Protasi F FASEB J; 2017 Aug; 31(8):3649-3662. PubMed ID: 28465322 [TBL] [Abstract][Full Text] [Related]
24. Assessing the pathogenicity of RYR1 variants in malignant hyperthermia. Merritt A; Booms P; Shaw MA; Miller DM; Daly C; Bilmen JG; Stowell KM; Allen PD; Steele DS; Hopkins PM Br J Anaesth; 2017 Apr; 118(4):533-543. PubMed ID: 28403410 [TBL] [Abstract][Full Text] [Related]
30. RYR1-related myopathies: a wide spectrum of phenotypes throughout life. Snoeck M; van Engelen BG; Küsters B; Lammens M; Meijer R; Molenaar JP; Raaphorst J; Verschuuren-Bemelmans CC; Straathof CS; Sie LT; de Coo IF; van der Pol WL; de Visser M; Scheffer H; Treves S; Jungbluth H; Voermans NC; Kamsteeg EJ Eur J Neurol; 2015 Jul; 22(7):1094-112. PubMed ID: 25960145 [TBL] [Abstract][Full Text] [Related]
31. Oral Dantrolene for Myopathic Symptoms in Malignant Hyperthermia-Susceptible Patients: A 25-Year Retrospective Cohort Study of Adverse Effects and Tolerability. Ibarra Moreno CA; Kraeva N; Zvaritch E; Jungbluth H; Voermans NC; Riazi S Anesth Analg; 2023 Mar; 136(3):569-577. PubMed ID: 36201369 [TBL] [Abstract][Full Text] [Related]
32. Screening for mutations in the RYR1 gene in families with malignant hyperthermia. Muniz VP; Silva HC; Tsanaclis AM; Vainzof M J Mol Neurosci; 2003; 21(1):35-42. PubMed ID: 14500992 [TBL] [Abstract][Full Text] [Related]
33. A rare genetic variant of the ryanodine receptor in a suspected malignant hyperthermia susceptible patient. MacKay EJ; Wilkerson C; Kraeva N; Rosenberg H; Kennedy T J Clin Anesth; 2016 Sep; 33():144-6. PubMed ID: 27555149 [TBL] [Abstract][Full Text] [Related]
34. Risk of malignant hyperthermia in patients carrying a variant in the skeletal muscle ryanodine receptor 1 gene. Janssens L; De Puydt J; Milazzo M; Symoens S; De Bleecker JL; Herdewyn S Neuromuscul Disord; 2022 Dec; 32(11-12):864-869. PubMed ID: 36283893 [TBL] [Abstract][Full Text] [Related]
35. Identification of genetic mutations in Australian malignant hyperthermia families using sequencing of RYR1 hotspots. Gillies RL; Bjorksten AR; Davis M; Du Sart D Anaesth Intensive Care; 2008 May; 36(3):391-403. PubMed ID: 18564801 [TBL] [Abstract][Full Text] [Related]
36. Identification of variants of the ryanodine receptor type 1 in patients with exertional heat stroke and positive response to the malignant hyperthermia in vitro contracture test. Roux-Buisson N; Monnier N; Sagui E; Abriat A; Brosset C; Bendahan D; Kozak-Ribbens G; Gazzola S; Quesada JL; Foutrier-Morello C; Rendu J; Figarella-Branger D; Cozonne P; Aubert M; Bourdon L; Lunardi J; Fauré J Br J Anaesth; 2016 Apr; 116(4):566-8. PubMed ID: 26994242 [No Abstract] [Full Text] [Related]
37. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). Roberts MC; Mickelson JR; Patterson EE; Nelson TE; Armstrong PJ; Brunson DB; Hogan K Anesthesiology; 2001 Sep; 95(3):716-25. PubMed ID: 11575546 [TBL] [Abstract][Full Text] [Related]